Sobi publishes Q1 2022 report
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter of 2022 January – March 2022 · Total revenue SEK 4,925 M (3,661), +35 per cent, +24 per cent at constant exchange rates (CER) · Haematology revenue SEK 2,499 M (1,877), +25 per cent at CER of which Elocta® SEK 1,024 M (857), +15 per cent at CER; Alprolix® SEK 419 M (413), -3 per cent at CER; Doptelet® SEK 593 M (180), +197 per cent at CER and Aspaveli®/Empaveli™ SEK 4 M (-) · Immunology revenue SEK 2,119 M (1,554), +24 per cent at CER of which Kineret® SEK